Prospective Observational Analysis Of CR With Sunitinib Treatment In mRCC Patients

CompletedOBSERVATIONAL
Enrollment

77

Participants

Timeline

Start Date

May 21, 2015

Primary Completion Date

January 19, 2022

Study Completion Date

January 19, 2022

Conditions
Complete Remission in Renal Cell Carcinoma
Interventions
DRUG

sunitinib

50 mg 4/2 ,oral, once a day 4 weeks on and 2 weeks off for 6 months

DRUG

sunitinib

50 mg 4/2 ,oral, once a day 4 weeks on and 2 weeks off for 6 months

Trial Locations (14)

13273

Institut Paoli-Calmettes, Marseille

13335

CHU de la Timone, Marseille

13385

Hopital Timone Adultes, Marseille

29000

C.H.U Morvan, Brest

34295

CRLC Val d'Aurelle, Montpellier

49933

CHRU HOTEL DIEU - Service Urologie, Angers

54511

Centre Alexis Vautrin, Vandœuvre-lès-Nancy

67010

Clinique Chirurgicale de l'Orangerie, Chiliotherapie, Strasbourg

67091

CHU Strasbourg, Strasbourg

69495

Centre Hospitalier Lyon Sud, Pierre-Bénite

72015

Clinique Victor Hugo, Le Mans

75908

Hopital Europeen Georges Pompidou, Paris

94805

Institut Gustave Roussy, Villejuif

13273 Cedex 9

Institut Paoli-Calmettes / Hôpital de jour, Marseille

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01934452 - Prospective Observational Analysis Of CR With Sunitinib Treatment In mRCC Patients | Biotech Hunter | Biotech Hunter